In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity? The post What are brokers saying about ...

Csl Ltd ( ($CSLLY) ) has released its Q2 earnings. Here is a breakdown of the information Csl Ltd presented to its investors.

Investing.com-- Australian biopharmaceutical giant CSL Ltd (ASX: CSL) reported a rise in half-year net profit, driven ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

In a report released today, Shane Storey from Wilsons maintained a Hold rating on CSL (CMXHF – Research Report), with a price target of ...

CSL's Seqirus vaccine unit saw revenue decline 9% YoY to $1.66 billion for the six months ended December 31, 2024, falling 15% short of analyst expectations. This weakness in the vaccine segment ...

At this point some shareholders may be questioning their investment in CSL Limited (ASX:CSL), since the last five years saw the share price fall 13%. The recent uptick of 3.6% could be a positive ...

Learn More CSL Ltd (ASX: CSL) shares couldn't avoid the broader market sell-off on Monday. Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock ended the day down 1.4%, trading for $276.42 apiece.

Learn More CSL Ltd (ASX: CSL) shares will be closely watched by Aussie investors next week. That's because the biotechnology giant is scheduled to release its half year results on Tuesday 11 February.